Discover
ORKA
Oruka Therapeutics, Inc.
93.29
2 x 68.04
2 x 119.82
bid
ask
-
1.88
1.98%
2 @ 04:25 AM
91.99 -1.30 (1.39%)
| Ytd | 207.79% | |
| 1y | 690.59% |
92.92
day range
96.14
11.82
52 week range
97.78
| Open | 94.15 | Prev Close | 95.17 | Low | 92.92 | High | 96.14 | Mkt Cap | 5.63B |
| Vol | 1.38M | Avg Vol | 1.78M | EPS | -1.93 | P/E | N/A | Forward P/E | -37.43 |
| Beta | N/A | Short Ratio | 5.62 | Inst. Own | 89.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 68.39 | 200-d Avg | 41.61 | 1yr Est | 142.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-13 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-12 | 2025-12 | 0 | N/A | 0.16 | 26.23% |
| 2025-11-12 | 2025-09 | 0 | N/A | 0.01 | 1.79% |
| 2025-08-11 | 2025-06 | 0 | N/A | 0.02 | 4.17% |
| 2025-05-14 | 2025-03 | 0 | N/A | 0.17 | 29.82% |
| 2025-03-06 | 2024-12 | 0 | N/A | 0.19 | 27.94% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-01 | UBS | Upgrade | Buy | Buy |
| 2026-06-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | BTIG | Upgrade | Buy | Buy |
| 2026-04-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-28 | UBS | Upgrade | Buy | Buy |
Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-21 | AGARWAL ARJUN | Officer | 15.31K | Sale |
| 2026-06-11 | DAMBKOWSKI CARL | Director | 38.74K | Sale |
| 2025-09-16 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2026-06-14 | GONCALVES JOANA | Officer | 32.72K | Sale |
| 2024-08-15 | JANUS HENDERSON GROUP PLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-14 | KLEIN LAWRENCE OTTO | Chief Executive Officer | 925.58K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 7.43M | 693.28M | 12.32% |
| 2026-03-30 | Venrock Adviser, LLC | 4.15M | 387.01M | 6.88% |
| 2026-03-30 | Fairmount Funds Management LLC | 3.71M | 345.66M | 6.14% |
| 2026-03-30 | Blackrock Inc. | 3.53M | 329.04M | 5.85% |
| 2026-03-30 | Viking Global Investors, L.P. | 2.67M | 248.78M | 4.42% |
| 2026-03-30 | Paradigm Biocapital Advisors LP | 2.32M | 216.46M | 3.85% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 128.25M | 2.28% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.22M | 113.91M | 2.02% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 910.56K | 84.95M | 1.51% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 842.04K | 78.55M | 1.40% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 833.10K | 77.72M | 1.38% |
| 2026-05-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 737.39K | 68.79M | 1.22% |
Dividend
| Dividend | Date |
|---|---|
| 1.613 | 2024-08-29 |